

1 **Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an** 2 **elderly cohort vaccinated with BNT162b2**

3 Joseph Newman^{1*}, Nazia Thakur^{1,2*}, Thomas P. Peacock^{3,4}, Dagmara Bialy¹, Ahmed ME
4 Elreafey¹, Carlijn Bogaardt⁵, Daniel L. Horton⁵, Sammy Ho⁴, Thivya Kankeyan⁴, Christine
5 Carr⁴, Katja Hoschler⁴, Wendy S. Barclay³, Gayatri Amirthalingam⁴, Kevin Brown⁴, Bryan
6 Charleston¹, Dalan Bailey^{1‡}

7

8 ¹ The Pirbright Institute, Guildford, Surrey, GU24 0NF, United Kingdom

9 ² Nuffield Department of Medicine, The Jenner Institute, Oxford, OX3 7DQ, United Kingdom

10 ³ Department of Infectious Disease, Imperial College – London, W2 1PG, United Kingdom

11 ⁴ UK Health Security Agency (UKHSA), UK

12 ⁵ Department of Pathology and Infectious Diseases, School of Veterinary Medicine, University
13 of Surrey

14

15 * These authors contributed equally to the work

16 ‡ Corresponding author: dalan.bailey@pirbright.ac.uk

17 **Abstract**

18 SARS-CoV-2 variants threaten the effectiveness of tools we have developed to mitigate
19 against serious COVID-19. This is especially true in clinically vulnerable sections of society
20 including the elderly. Using sera from BNT162b2 (Pfizer–BioNTech) vaccinated individuals
21 aged between 70 and 89 (vaccinated with two doses 3-weeks apart) we examined the
22 neutralising antibody (nAb) response to wildtype SARS-CoV-2. Between 3 and 20-weeks post
23 2nd dose, nAb titres dropped 4.9-fold to a median titre of 21.3 (ND80) with 21.6% of individuals
24 having no detectable nAbs at the later time point. Experiments examining the neutralisation of
25 twenty-one different SARS-CoV-2 variant spike proteins confirmed a significant potential for
26 antigenic escape, especially for the Omicron (BA.1), Beta (B.1.351), Delta (B.1.617.2), Theta
27 (P.3), C.1.2 and B.1.638 variants. Interestingly, however, the recently-emerged sub-lineage
28 AY.4.2 was more efficiently neutralised than parental Delta pseudotypes. Combining
29 pseudotype neutralisation with specific receptor binding domain (RBD) ELISAs we confirmed
30 that changes to position 484 in the spike RBD were predominantly responsible for SARS-CoV-
31 2 nAb escape, although the effect of spike mutations is both combinatorial and additive. Lastly,
32 using sera from the same individuals boosted with a 3rd dose of BNT162b2 we showed that
33 high overall levels of neutralising antibody titre can provide significant levels of cross-
34 protection against Omicron. These data provide evidence that SARS-CoV-2 neutralising
35 antibodies wane over time and that antigenically variable SARS-CoV-2 variants are
36 circulating, highlighting the importance of ongoing surveillance and booster programmes.
37 Furthermore, they provide important data to inform risk assessment of new SARS-CoV-2
38 variants, such as Omicron, as they emerge.

39

40 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Introduction

41 The effects of the COVID-19 pandemic have, in some countries, been mitigated by the
42 implementation of highly efficacious vaccines, which have reduced hospitalisations and
43 deaths. In late 2020 and early 2021 this was widely achieved (in the UK, France and
44 elsewhere) through vaccination with BNT162b2 (Pfizer–BioNTech) – a lipid nanoparticle-
45 formulated, nucleoside-modified RNA vaccine encoding prefusion stabilized SARS-CoV-2
46 spike; or ChAdOx1 nCoV-19 (AZD1222, Oxford–AstraZeneca), an adenoviral-vectored
47 vaccine expressing wild-type (non-stabilised) spike [1, 2]. Initially in the UK, for BNT162b2,
48 two doses of this vaccine were administered 3-weeks apart, with many of the most clinically
49 vulnerable (within the nine priority groups established by the UK’s Joint Committee on
50 Vaccination and Immunisation [JCVI]) receiving their vaccines with this dosing interval.
51 However, in the UK, this schedule was quickly changed to ‘up to 12-weeks’, to maximise use
52 of limited supplies of these vaccines and to protect the largest possible number of people from
53 developing serious disease. This remained the strategy as vaccination was extended to the
54 priority groups further down JCVI’s list (stratification based primarily on age), before being
55 opened up to all adults later in 2021, as well as children over 12. Third doses, as well as
56 boosters, are also now available to all adults [3]. To date, detailed information on vaccine
57 responses in elderly populations (>65) vaccinated with BNT162b2 3-weeks apart is lacking, in
58 particular data on neutralising antibody (nAb) titres over time, correlations between ELISA and
59 nAb titres, cross-protective nAb titres against SARS-CoV-2 variants, and the role of boosters
60 in enhancing this cross protection. These data are relevant to elderly cohorts in the UK, but
61 also internationally where the 3-week interval between doses is followed. Neutralising
62 antibodies in the elderly are of especial significance, as it is well established that vaccine
63 responses in this demographic are less robust [4, 5], and this group may represent a
64 vulnerable cohort for SARS-CoV-2 variants.

65 Whereas the SARS-CoV-2 virus that caused the first global wave had little genetic, antigenic
66 or other phenotypic diversity, subsequent waves comprised extremely diverse SARS-CoV-2
67 ‘variants’, defined by genetic, antigenic and phenotypic divergence from preceding strains [6].
68 The most widespread or concerning of these were classified by the World Health Organisation
69 (WHO) and/or UKHSA as ‘variants of concern (VOC)’, ‘variants of interest/variants under
70 investigation’ (VOI, WHO; VUI, UKHSA) or ‘variants under monitoring’ VUM; these VOCs and
71 VUIs were subsequently given Greek letter identifiers [7]. The first described of these, the
72 Alpha variant (Pango lineage B.1.1.7), emerged in the UK around Autumn 2020 and showed
73 higher transmissibility than previous variants [8, 9]. The VOC Beta/B.1.351 was detected at a
74 similar time in South Africa, with the VOC Gamma/P.1 identified in Brazil not long after. All
75 three of these VOCs showed antigenic distance from the original strain, the spike protein of
76 which is used as the immunogen in BNT162b2 and ChAdOx1 nCoV-19 vaccines [10, 11].
77 From the start of 2021 many further variants, arose throughout the world, including B.1.1.318,
78 C.36.3, P.3, Mu/B.1.621, B.1.620, B.1.617.3, Lambda/C.37, A.30, AT.1, B.1.638, and C.1.2,
79 with some being designated as VUIs/VUMs, [12-14]. In April 2021 a new variant, Delta
80 (B.1.617.2), rapidly spread across the world after its initial detection in India [15, 16]. Although
81 Delta shows only modest antigenic divergence from the original SARS-CoV-2 strains it has
82 the highest transmissibility of any variant studied to date. Indeed, by November 2021, Delta
83 had largely displaced all other variants and comprises nearly all global sequences, with small,
84 localised pockets of Alpha, Gamma, Mu, B.1.1.318 and C.1.2 remaining but slowly declining
85 [14]. However, a Delta sub-lineage, AY.4.2, has recently arisen in the UK and shows tentative
86 signs of increased prevalence, gradually replacing other Delta sub-lineages [13]. In late
87 November 2021 the Omicron (BA.1, initially denoted B.1.1.529) variant was first detected in

88 southern Africa (specifically Botswana and South Africa), with isolations found across the
89 globe in the following days and weeks. Early data on increased transmissibility, community
90 displacement of Delta and evidence for significant antigenic variation support its immediate
91 classification as a VOC (Omicron) [17-20].

92 To examine antibody levels and T-cell responses following the extension to the COVID-19
93 vaccine schedule the UKHSA (formerly Public Health England, PHE) initiated a prospective
94 longitudinal audit of vaccinated adults (the CONSENSUS study). Within CONSENSUS, a
95 cohort of volunteers aged between 70 and 89 received the BNT162b2 vaccine 3-weeks apart.
96 In our study, using sera from 37 individuals in this cohort, we investigated the impact of waning
97 immunity on neutralisation of SARS-CoV-2, the correlation between ELISA, RBD-ELISA and
98 nAb titres, as well as the impact of various SARS-CoV-2 VOCs and VUMs/VUIs on viral
99 neutralisation. These data indicate that this clinically vulnerable priority group may be
100 especially susceptible to repeat infection with SARS-CoV-2 variants that are antigenically
101 distinct from the originally emerged strain; however, a 3rd dose of BNT162b2 can mitigate
102 against this risk. This susceptibility is the result of low overall nAb titres and appears to be
103 mechanistically defined by specific changes to the SARS-CoV-2 spike RBD, in particular E484
104 changes. These data provide a key tool for risk assessing current and future SARS-CoV-2
105 variants, including Omicron/BA.1 or sub-lineages (BA.2).

106 **Results**

107 Using a SARS-CoV-2 spike pseudotype-based micro-virus neutralisation assay (mVNT), we
108 determined neutralisation titres (ND80s) in 37 UK-based participants (median age 78 years
109 [IQR 75-80]) who had been vaccinated with BNT162b2 (Pfizer–BioNTech) 3-weeks apart
110 (median 21 days [IQR 21-21]). Titres from samples taken at 3 (n=37, median 22 days [IQR
111 22-23] and 20-weeks (n=35, median 135 days [IQR 134-136.5]) post 2nd dose immunisations
112 were initially evaluated with D614-based (wild-type [WT]/Wuhan) pseudotypes to match the
113 BNT162b2 immunogen. Dividing the cohort by age into individuals aged 70-79 (n=24, median
114 age 77 years [IQR 73.5-80]) and 80-89 years old (n=13, median age 81 years [IQR 80-84])
115 we observed median titres (ND80) of ≤ 128.1 (IQR 28.03-231.2) and ≤ 62.6 (IQR 25.45-129.6),
116 respectively, at 3-weeks post-vaccination. At 20-weeks post-vaccination these titres had
117 dropped to ≤ 24.84 (ages 70-79; IQR 14.59-61.46) and ≤ 16.0 (ages 80-89; IQR 10-24.34), a
118 median reduction of ≤ 5.2 -fold and ≤ 3.9 -fold, respectively (Figure 1A-B; exemplar RLU data
119 provided in Supplemental figure 1 A-B). At 3-weeks post 2nd dose 3/24 (12.5%) of 70-79 year
120 olds and 3/13 (23.1%) of 80-89 year olds had no detectable neutralising antibodies (ND80 =
121 ≤ 10 ; limit of assay detection), with this increasing to 4/22 (18.2%) and 4/13 (30.8%),
122 respectively, at 20-weeks. The 3-week ND80 titres were also converted to IU/ml, based on
123 comparisons to WHO's international standard for SARS-CoV-2 serological assays (NIBSC
124 code: 20/136) (Supplemental Figure 1C; median titres; ages 70-79, 344.5 IU/ml, 80-89, 168.3
125 IU/ml). The same sera samples were previously analysed [21] by ELISA (Roche Elecsys anti-
126 SARS-CoV-2 S ECLIA) and there was a strong correlation between mVNT and ELISA titres
127 in both age groups (70-79, Spearman $r = 0.84$, Figure 1C; 80-89, Spearman $r = 0.91$, Figure
128 1D).

129 The same 3 weeks post 2nd dose sera were subsequently used to investigate neutralisation of
130 pseudotypes bearing the SARS-CoV-2 spike from VOCs Alpha (B.1.1.7), Beta (B.1.351) and
131 Delta (B.1.617.2), as well as the D614G-containing lineage B.1 (Figure 2A). 4/24 (16.7%) of
132 70-79 year olds and 5/13 (38.5%) of 80-89 year olds had no detectable neutralising antibodies

133 (ND80 = ≤ 10 ; limit of assay detection) to Delta at this time point, while 16/24 (66.7%) and
134 11/13 (84.6%) of 70-79 and 80-89 year olds, respectively, had no identifiable response to Beta
135 (Figure 2B-C). When compared to D614G (median ND80 ≤ 333.3 ; IQR 62.53-642.9), in the 70-
136 79 age group, there was a ≤ 1.1 -fold (median ND80 ≤ 300.0 ; IQR 53.89-592.8) reduction in
137 neutralisation of Alpha, a ≤ 9.0 -fold drop with Delta (median ND80 ≤ 37.0 ; IQR 12.9-68.6) and
138 a ≤ 33.3 -fold drop with Beta (median ND-80 ≤ 10.0 ; IQR 10-16.34) (Figure 2B). In the older age
139 group (ages 80-89) the median titres were D614G ≤ 139.0 (IQR 39.15-316.2), Alpha ≤ 136.6
140 (IQR 43.54-334.3), Delta ≤ 12.4 (IQR 10-47.31) and Beta ≤ 10 (IQR 10-10) (Figure 2C). For
141 Delta and Beta this equated to a drop in neutralising titre of 11.2-fold and 13.9-fold,
142 respectively. Neutralising titres to Delta at 20-weeks post-vaccination were slightly lower,
143 consistent with the waning antibody response evidenced in Figure 1 (Supplemental Figure 2A-
144 B). However, there was evidence of affinity maturation in some individuals, especially to the
145 Beta VOC, although the median value remained unchanged (Supplemental Figure 2C-D).
146 VNT assays with replication competent SARS-CoV-2 WT D614 and the Beta VOC also
147 identified a reduction in neutralisation for Beta, with the calculated titres correlating well with
148 the mVNT pseudotype data (Supplemental Figure 3). Comparing the S ELISA (Roche Elecsys
149 anti-SARS-CoV-2 S ECLIA) with VOC ND80 titres we identified a strong correlation for D614G
150 (Spearman $r = 0.86$), Alpha ($r = 0.83$) and Delta ($r = 0.86$) neutralisation titres but a poor
151 correlation with Beta ($r = 0.52$) (Figure 2D). To investigate the mechanisms underpinning the
152 drop in neutralisation seen for specific VOCs we next performed a targeted ELISA with the
153 same sera and recombinant RBDs reflecting WT SARS-CoV-2, Alpha, Delta and Beta spike
154 sequences. In both the 70-79 and 80-89 age groups there was no significant difference in
155 ELISA titres between WT, Alpha and Delta RBDs (Figure 2E-F); however, there was a
156 significant reduction in binding to the Beta RBD (70-79, 2.9-fold compared to WT; 80-89, 2.2-
157 fold), partially correlating with the mVNT results. The S ELISA and RBD-ELISA data (both
158 based on antigens representing WT SARS-CoV-2 spike sequence) showed a strong
159 correlation (Spearman $r = 0.93$), indicative of good agreement between the two assays (Figure
160 2G). However, the correlation between RBD-ELISA and ND80 titres was again poor for the
161 Beta VOC (Spearman $r = 0.49$), albeit relatively consistent for the WT ($r = 0.83$), Alpha ($r =$
162 0.80) and Delta ($r = 0.86$) RBD-ELISAs.

163 Using a smaller representative pool of sera from the same cohort (3-weeks post 2nd dose;
164 $n=16$ total; 70-79, $n=11$; 80-89 $n=5$), selected by ranking the neutralisation responses of the
165 whole cohort, we widened our analysis to fifteen other SARS-CoV-2 variants, including other
166 VUIs and VUMs, in particular AY.4.2 (Figure 3A). This timepoint was chosen as the titres were
167 higher at 3- rather than 20-weeks post 2nd dose. Several variants showed a significant
168 reduction in neutralisation when compared to D614G (B.1); namely B.1.1.318 (2.9-fold), A.30
169 (2.0-fold), B.1.617.3 (1.6-fold), B.1.621/Mu (3.0-fold), P.3/Theta (7.2-fold), C.1.2 (10.8-fold),
170 Mu + K417N (3.2-fold), B.1.638 (8.5-fold), AY.4.2 (3.4-fold), and Delta + A222V (2.8-fold)
171 (Figure 3B). Of note, experiments were always performed with a D614G pseudotype control
172 and we showed a good concordance between calculated D614G ND80 titres from individual
173 experiments, highlighting the robust repeatability of our assay and the capacity to compare
174 mVNT titres across data sets (Supplemental Figure 4). Aside from Delta and AY.4.2, which
175 contain the L452R and T478K RBD mutations, all of these variants contain mutations at RBD
176 position 484. Furthermore, for P.3 (Theta), C.1.2 and B.1.638, 4/16 (25.0%), 5/16 and 5/16
177 (31.3%) of the individuals, respectively, had no detectable neutralising antibodies (ND80 =
178 ≤ 10 ; limit of assay detection) to these variants at this time point post-vaccination (for Beta
179 VOC this was 9/16 (56.3%) [calculated from data presented in Figure 2B-C]). Interestingly, the

180 median titres to Delta (≤ 49.2 , IQR 14.24-190.3) were lower than the AY.4.2 (≤ 82.2 , IQR 24.52-
181 82.19) and Delta + A222V (≤ 100.0 , IQR 25.67-211.5) variants, despite the presence of
182 additional mutations in these spike proteins.

183 To provide better spatial representation of the antigenic relationships between the different
184 variants, we also performed antigenic cartographic analysis on the collated ND80 titres from
185 a sub-set of the sera (3 weeks post second-dose, $n=14$) tested against all available VOCs,
186 VUIs and VUMs in mVNTs. Antigenic cartography allows high resolution quantitative
187 comparison and visualisation of antigenic relationships. Antigenic distances between antigens
188 on the map are measured in antigenic units, with one antigenic unit (AU) being the equivalent
189 of a two-fold dilution in titre. The antigenic map of ND80 titres (Figure 3C) again highlights the
190 largest antigenic distance is between D614G and Beta (5.3 AU). Other variants located at an
191 intermediate distance from D614G are C.1.2 (4.0 AU), P.3/Theta (3.5 AU), B.1.621/Mu (3.3
192 AU), B.1.638 (3.3 AU), Delta (3.1 AU), B.1.1.318 (2.9 AU), Mu + K417N (2.8 AU), A.30 (2.5
193 AU), B.1.620 (2.3 AU), AT.1 (2.2 AU), AY.4.2 (2.0 AU), B.1.617.3 (1.9 AU), Delta + A222V
194 (1.9 AU), and C.37/Lambda (1.2 AU). The WT/Wuhan (D614) virus, C.36.3, B.1.214.2 and
195 Alpha are all located close (1 AU or less) to D614G. The sera are all located in one part of the
196 map, and not far from Wuhan and D614G viruses; this is as expected from sera from recipients
197 of the same WT/Wuhan spike-based vaccine with similar neutralization profiles. This
198 clustering of sera means interpretation of the distances between the most divergent SARS-
199 CoV-2 variants on the antigenic map (e.g P.3 to Beta) is less reliable than their distances to
200 D614G, demonstrated by the confidence coordination areas for their positions (Supplemental
201 Figure 5A). In addition, to identify the amino acid changes within the RBD responsible for the
202 significant drop in neutralisation in this cohort we repeated the WT, Alpha, Delta and Beta
203 RBD-ELISAs, extending the analysis to include RBDs with single amino acid changes at
204 positions K417, L452, T478 or E484. The only changes that led to a significant drop in binding
205 were K417N (1.2-fold), E484K (1.6-fold) and E484D (1.4-fold), highlighting the importance of
206 these positions in escape from neutralisation (Figure 3D, and antigenic map in Supplemental
207 Figure 5B/C).

208 In November 2021 the BA.1 (Omicron) VOC was first detected in Southern Africa, rapidly
209 spreading across the globe. By mid-December 2021 infections were highly prevalent in the
210 UK and many other countries. At this time many of the volunteers in the CONSENSUS trial
211 had received their 3rd dose. To understand antigenic changes to the Omicron spike, which has
212 extensive deletions and substitutions (Figure 4A), we performed mVNT assays for all
213 volunteers where a 3rd dose sample was available ($n=19$; 70-79, $n=12$; 80-89, $n=7$). These
214 samples were taken 4 weeks after the booster (median 28 days [IQR 28-28]). At 3 weeks post
215 2nd dose 10/12 (83%) of 70-79 year olds and 6/7 (86%) of 80-89 year olds had no detectable
216 neutralising antibodies (ND80 = ≤ 10 ; limit of assay detection) to Omicron (Figure 4B-C). At 20
217 weeks post 2nd dose this was 92% and 86%, respectively. However, at 4 weeks following the
218 3rd dose all volunteers now, significantly, had detectable titres against Omicron (Figure 4B-C).
219 In the 70-79 age group, when compared to D614G (median ND80 ≥ 530.7 ; IQR 318.3-883.4),
220 there was a 53.1-fold reduction (median ND80 ≤ 10 ; IQR 10-10) in neutralisation of Omicron
221 at 3 weeks post vaccination, but only an 8.0-fold (D614G; median ND80 ≥ 3070.9 ; IQR 1498.4-
222 3798.1 vs Omicron; median ND80 384.3; IQR 189.7-735.7) drop 4 weeks after the 3rd dose
223 (Figure 4B). In the older age group (ages 80-89) the median titres for D614G were 1354.1
224 (IQR 953.3-2103.9) after the 3rd dose, whilst for Omicron this was 80.8 (IQR 59.5-239.2),
225 Figure 4C), a 16.8-fold reduction. Correlating the S ELISA (Roche S1) values for these

226 samples with their Omicron ND80 titres further illustrates the improved neutralisation titres
227 following a 3rd dose of vaccination and also identified an improved correlation between ND80
228 and ELISA (20 weeks post 2nd dose, Spearman $r = 0.53$; 4 weeks post 3rd dose, Spearman
229 $r=0.82$ Figure 4D-E).

230 **Discussion:**

231 At a global level many elderly populations have been protected from COVID-19 by the
232 implementation of mass vaccination. However, lower overall Ab responses and concerns of
233 waning immunity in elderly vaccinees have highlighted the potential impact of antigenically
234 distinct variants on controlling this disease. Using sera from an elderly cohort double-
235 vaccinated with BNT162b2 we demonstrated significantly reduced neutralisation of the Delta
236 and Beta VOCs, which is compounded by waning immunity (Figures 1-2); data which
237 correlates with previously published findings. Noori et al., performed a systematic review of
238 the potency of BNT162b2 vaccine-induced nAbs against SARS-CoV-2 VOCs from 36 different
239 publications and identified a similar trend, with Beta being the least sensitive to neutralisation
240 and Delta having intermediate sensitivity [22]. Similarly, a Delta-focused review by Bian et al.,
241 examining a broader selection of studies on BNT162b2 or ChAdOx1 vaccinees, as well as
242 convalescent individuals, identified the same pattern of VOC neutralisation [23]. Indeed,
243 across the collated studies there were numerous examples of Beta being neutralised >10-fold
244 less efficiently than D614 or D614G (22.11-fold [24], 11.13-fold [25] and 13.32-fold [26]).
245 Focusing on the study by Liu et al. [26], they identified a 7.56-fold reduction in neutralisation
246 of Beta in BNT162b2-vaccinated individuals when compared to a virus isolated early in the
247 pandemic. Differences in fold-reduction can be attributable to experimental variation (lab-to-
248 lab, live virus vs. pseudotype) or specific characteristics of the cohort, such as age. For
249 example, the BNT162b2-vaccinated cohort analysed by Liu et al. represents health care
250 workers with a mean age of 37 (range 22-66), whereas our study targeted an elderly cohort
251 aged 70-89. One interpretation is that the low nAb titres we and others have seen in elderly
252 vaccinees [27, 28] may contribute disproportionately to the lack of neutralisation of
253 antigenically distinct SARS-CoV-2 variants. Confirming this hypothesis would require detailed
254 comparison of the polyclonal B-cell response in various age-groups; however, Greaney et al.,
255 demonstrated the response is skewed to a single class of antibodies which target an epitope
256 in the RBD encompassing position 484, which is substituted in Beta (E484K) [29]. One
257 limitation of our study is that for some VOCs, e.g. Beta, almost all the sera dropped below the
258 limit of detection of our assay (ND80 of 10), providing less granularity, complicating
259 comparisons with other studies, and obfuscating correlations with more sensitive Ab-detection
260 assays such as the RBD-ELISA.

261 Elsewhere, our data on Omicron neutralisation following 2 doses of BNT162b2 fits with
262 recently reported findings. Dejnirattisai et al., Cameroni et al., and Garcia-Beltran et al. all
263 showed drops in neutralisation of >30-fold [18-20, 30]. However, it is clear from our data, and
264 that of Garcia-Beltran et al., [20] that boosting with a 3rd dose of BNT162b2 generates a much
265 higher overall titre of neutralising antibodies to D614G (median ND80 ≥ 3070.9 in the 70-79
266 age group, Figure 4B) and that these high titres enhance cross-protection against Omicron
267 and mitigate against the significant drops in neutralisation seen after two doses, highlighting
268 the important role of boosters in providing robust long-term immunity to SARS-CoV-2.

269 A smaller pool of antigenicity data is available on the wide range of other variants (VUIs/VUMs)
270 that have emerged since the beginning of the pandemic. Our data highlighted several

271 important antigenically-divergent variants, in particular C.1.2 and B.1.638 (Note: B.1.638 is
272 from a small isolated outbreak; n=13), both initially detected in South Africa [31]; B.1.621 (Mu),
273 first detected in Colombia [32] and P.3 (Theta) – isolated in the Philippines [33]. We identified
274 a 3.0-fold and 10.8-fold reduction in neutralisation for Mu and C.1.2, respectively (Figure 3B),
275 and antigenic distances of 4AU (C.1.2) and 3.3AU (Mu) (Figure 3C), which are concordant with
276 observations by Tada et al. in BNT162b2-vaccinated individuals (Mu, 6.8-fold reduction; C.1.2,
277 7.3-fold) [34]. The same authors showed similar Mu and C.1.2-specific reductions in
278 neutralisation in sera from convalescent individuals as well as mRNA-1273 (Moderna)
279 vaccinees [34]. There was less agreement with the study by Uriu et al; these authors showed
280 that Mu was more antigenically diverse than Beta (9.1-fold vs. 7.6-fold reduction with
281 BNT162b2-vaccine serum) [35]. Similarly, Arora et al. identified that A.30 was more
282 antigenically distinct from Beta when tested with BNT162b2 sera (4.6-fold vs. 3.3-fold) [36],
283 whilst in our study A.30 resulted in only a 2.0-fold drop in neutralisation and a position only
284 2.5AU from D614G (Figure 3B). As discussed above these differences might be attributable
285 to laboratory or cohort-specific factors. Nevertheless, the main strength of our approach has
286 been to use a single set of sera to compare the relative neutralisation of VOCs and VUIs/VUMs
287 (Figure 3).

288 As summarised by Harvey et al., [37] our molecular understanding of SARS-CoV-2 variant
289 spike mutations and immune escape is now relatively well-established, permitting the
290 mechanistic contextualisation of these neutralisation data. The most pertinent question raised
291 by our data set is, 'why are Omicron and Beta so bad?'. From a variant monitoring perspective,
292 the answers to this question can be used as a framework to understand other SARS-CoV-2
293 variants, old or new. Since Omicron has so many changes in its spike protein, it is difficult to
294 draw any meaningful conclusions without doing targeted mutagenesis. However, a number of
295 the other variants share enough similarity to Beta that useful comparisons and conclusions
296 can be drawn by correlating individual mutations to varied antigenicity. Compared to variants
297 such as Omicron or B.1.638, the spike mutation profile of Beta is relatively simple, with only 9
298 changes (Figure 3A). Focusing on the RBD, the amino acid changes K417N and E484K are
299 well associated with antigenic escape from monoclonal antibodies and the polyclonal B-cell
300 response [22, 23, 29]. Changes at position 417 affect class 1 Ab binding while 484
301 modifications affect the epitope bound by class 2 Abs, which dominate the polyclonal response
302 to the RBD [37]. The importance of these particular RBD-changes to Ab-binding was
303 confirmed by our RBD-ELISA (Fig.2E-F and Fig.3D). Of the single amino acid mutated RBDs
304 we assessed, only those containing K417N (1.2 fold) or E484K/D (E/K, 1.6-fold; E/D, 1.4-fold)
305 significantly reduced Ab-binding, when compared to WT. The E484D change, although not
306 present in any variant we analysed, has previously been implicated in escape from monoclonal
307 nAbs [37]. Combining these changes with N501Y in the Beta RBD appeared to be additive
308 and led to a concomitant 2.2-fold reduction in Ab-binding, indicating that the loss of Beta VOC
309 neutralisation we, and others [22], have observed (Figure 2B-C) is due to a reduction in class
310 1 and 2 nAb binding. Interestingly, the magnitude of reduction for the complete Delta RBD
311 (1.1-fold) or Delta-specific single amino acid RBD substitutions was lower (L452R, 1.1-fold) or
312 the same as K417N (T478K, 1.2-fold) and non-significant in our studies (Figure 3D). This might
313 explain the more moderate reductions in neutralisation seen with this VOC (Figure 2B-C) or
314 point to another region of the Delta spike being responsible for antigenic variance. Further,
315 our RBD-ELISA data on E484Q, which only moderately reduced Ab-binding (1.1-fold) might
316 explain the relatively minor effects of B.1.617.3 on neutralisation (1.6-fold reduction, relative
317 to D614G, Figure 3B).

318 Another interesting observation was to compare the contribution of 484 changes to
319 neutralisation when in the context of other RBD changes. When present as the only RBD
320 mutation (AT.1, 1.7-fold and 2.2AU; B.1.1.318, 2.9-fold and 3 AU), or with additional RBD
321 changes which we demonstrated do not significantly affect Ab-binding in RBD-ELISAs, e.g.
322 L452R (B.1.617.3, 1.6-fold and 1.9AU), E484K had only moderate effects on pseudotype
323 neutralisation. However, the addition of N501Y (which is also present in Beta, Mu, Theta and
324 C.1.2) seemed to enhance escape from neutralisation, e.g., P.3/Theta (7.2-fold, 3.5AU).
325 Although there is some evidence that N501Y modifies antigenicity [38], the presence of this
326 mutation in Alpha does not appear to affect its neutralisation (Figure 2B-C, [39]). Moreover,
327 this substitution has most frequently been mechanistically linked to an increase in affinity for
328 ACE2 [40]. In the context of neutralisation of E484-mutated variants it may be that the
329 increased affinity of N501Y for ACE2 has a compound effect on class 2 antibodies trying to
330 bind spike, as these antibodies' affinities for spike have already been reduced by, for example,
331 the E484K substitution. We recently showed that the RaTG13 spike is efficiently neutralised
332 by SARS-CoV-2-specific sera, which was surprising given the large number of RBD
333 substitutions between these two spike proteins [41]. However, the affinity of RaTG13 spike for
334 human ACE2 is markedly lower than SARS-CoV-2 spike [42] - it is likely therefore that a limited
335 pool of higher affinity antibodies to RaTG13 spike can effectively outcompete this interaction,
336 permitting neutralisation, with perhaps the opposite being true in a N501Y-containing SARS-
337 CoV-2 spike. Making conclusions on Beta mutations which lie outside of the RBD is slightly
338 more challenging, with C1.2 or Mu/B.1.621 being perhaps the best comparator. The Mu +
339 K417N variant spike we analysed (3.2-fold reduction in neutralisation and 2.1 AU from D614G)
340 has almost the same RBD as Beta (albeit Mu additionally has R346K); however, the N-terminal
341 domains (NTD) are distinct. Beta has a deletion between amino acid positions 242-244 [43],
342 recurrently deleted region 4 (RDR4), which corresponds to exposed loops on the surface of
343 the spike NTD. RDR4 deletions have previously been associated with the loss of monoclonal
344 antibody binding (4A8)[43]. Likewise, L18F also sits within the NTD supersite and its
345 modification may also affect antibody binding.

346 To summarise, the significant antigenic escape properties of Beta and Omicron are likely the
347 result of a combination of changes to the spike protein, which act in synergy and in an additive
348 manner to avoid Ab-recognition, with the other variants we tested lacking some or all of these
349 features. These hypotheses could be tested by introduction of K417N into C.1.2, the 242-244
350 deletion into Mu + K417N, or by selected deletion of mutations in Omicron. Of note, this
351 research should only be performed in the context of spike expression plasmids for
352 pseudotyping, and not in gain-of-function experiments with recombinant viruses. Of note, it is
353 also worth highlighting that antigenic changes to spike are not the only defining feature of
354 SARS-CoV-2 variants. For instance, Alpha and Delta have risen to global dominance over
355 Beta, likely because of changes elsewhere in spike that affect infectivity and transmissibility
356 [44] or indeed changes elsewhere in the genome, which affect other phenotypic characteristics
357 of the virus such as innate immune regulation [45]. Nevertheless, these detailed antigenic data
358 can be used as a reference for risk assessment of emerging SARS-CoV-2 variants.

359 Focusing on the UK situation momentarily: the UK has extensive monitoring programmes for
360 SARS-CoV-2 which are combined with genomic sequencing to identify novel variants as and
361 when they emerge or are introduced [13]. From the summer of 2021 onwards a sub-lineage
362 of Delta, AY.4.2, has increased in prevalence, and in the last 28 days (up to 10-12-2021) has
363 accounted for 18.2% of the genotyped isolates (<https://sars2.cvr.gla.ac.uk/cog-uk/>). This
364 variant, which early data indicates may have higher transmissibility [46], has two additional

365 changes in the spike NTD, Y145H and A222V. Interestingly, despite these additional changes,
366 pseudotypes bearing the AY.4.2 spike as well as Delta + A222V alone were more efficiently
367 neutralised by sera from our BNT162b2-cohort (Figure 3) when compared to Delta (albeit not
368 significantly; Wilcoxon matched-pairs signed rank test). These data are similar to those
369 reported by Lassauniere et al., who also examined BNT162b2 mRNA vaccine-elicited sera
370 [47]. A222V is the second most common substitution in SARS-CoV-2 Spike (after D614G), yet
371 to date had no established phenotypic impact on spike function [37]. It remains unclear why
372 A222V increases the neutralisation of Delta; however, this could relate to increased
373 accessibility of the RBD to nAbs. It remains to be seen how the prevalence of AY.4.2 will be
374 affected by the introduction of Omicron to the UK; however, epidemiologists are predicting that
375 Delta and its sub-lineages will soon be replaced by this new variant [13].

376 Another pertinent question that our data set raises is whether spike-based ELISA titres
377 correlate well with virus (or pseudovirus) neutralisation titres. From a practical perspective, if
378 ELISAs can be used to establish an immune threshold that in turn reliably correlates with a
379 certain level of nAbs, then that would be advantageous for clinical management of COVID-19.
380 This is especially true if a threshold can easily be established for each variant as and when
381 they emerge. Unfortunately, whilst our data on a BNT162b2-vaccinated elderly cohort
382 identified a reliable correlation between WT (D614 or D614G), Alpha and Delta, it was
383 disrupted by more antigenically distinct variants like Beta (Figure 2) and Omicron (Figure 4D).
384 Whilst the RBD-ELISA with a Beta RBD was useful for mechanistically underpinning our
385 understanding of ‘why Beta is so bad’, and the antigenic relationships were largely consistent
386 between mVNT and ELISA using antigenic maps, the results did not improve the correlation
387 with neutralisation titres, although a better correlation exists with higher titre sera. However, a
388 major limitation of our findings is that our mVNT was clearly less sensitive than the ELISA or
389 RBD-ELISA, with many Beta mVNTs falling below the limit of detection (<10 ND80). A younger
390 cohort, one sampled from vaccinees who had the extended interval between 1st and 2nd dose
391 [48], or people who receive a 3rd dose (Figure 4) who collectively have higher overall titres,
392 might represent a better benchmark for understanding and testing this correlation in more
393 detail.

394 A younger cohort, including recipients of other vaccines, could also improve the resolution of
395 the antigenic maps. Antigenic cartography offers great potential as a robust and repeatable
396 way to measure antigenic changes among variants, and test hypotheses on the effect of
397 individual and combinations of spike protein mutations [49, 50]. However, using sera with
398 similar neutralisation profiles and from volunteers with unknown history of exposure to other
399 viruses limits the resolution of the maps [51]. Using sera from other species with a known
400 exposure history has also demonstrated its utility in rigorous comparison of antigenic
401 distances, overcoming these issues [52].

402 **Concluding remarks**

403 In summary, our data highlight the propensity of certain SARS-CoV-2 variants to partially avoid
404 vaccine-derived immunity. The BNT162b2-vaccinated elderly cohort we investigated showed
405 evidence of waning immunity at 20-weeks post-vaccination, which could potentially
406 exacerbate this escape. However, high titres could be rescued with a 3rd dose, which provided
407 cross-protective immunity against Omicron. Developing a better understanding of how these
408 titres relate to a well-defined correlate of immunity will be an important step in understanding
409 the wider implications of this data on the management of COVID-19 and whether the risk of

410 breakthrough infections, hospitalisation and deaths is increased, either by waning immunity or
411 new variants. Interestingly, three of the vaccinated volunteers in our study were SARS-CoV-2
412 N Ab positive (Elecys® Anti-SARS-CoV-2 N, Roche), indicative of previously resolved
413 infections. The nAb and ELISA titres from two of these individuals were the highest in our
414 cohort, supporting observations that infection and vaccination provide a robust Ab response
415 to SARS-CoV-2 [53]. Clearly, we can achieve similar titres through boosting (Figure 4);
416 however, whether boosting provides as broad a response as natural infection in this context
417 remains to be determined. Interestingly, it is clear from various studies that responses to
418 infection and/or vaccination can be variant-specific, and that neutralisation of homologous
419 variants is superior to heterologous [54, 55]. For example, Liu et al., showed that sera from
420 convalescent individuals who had been infected with Beta and Gamma VOCs showed superior
421 responses to these matched variants in VNTs, but reduced neutralisation of Delta [26]. For
422 Delta, which does not appear that antigenically distinct from the ‘vaccine strain’, it may not be
423 necessary to tailor the Ab response with variant-specific boosters, a conclusion that our data
424 indicates might also be true for Omicron. To conclude, research comparing the antigenicity of
425 SARS-CoV-2 variants and elucidating the role of individual mutations is vital in the
426 management of the Covid-19 pandemic and in predicting the outcome of new variants. At a
427 clinical level this information can be leveraged by policymakers to determine the most
428 appropriate vaccination strategy to protect the most vulnerable groups in society.

429 **Acknowledgements:**

430 We would like to acknowledge the whole of the UKHSA (formerly PHE) CONSENSUS team,
431 as well as the vaccinated volunteers for their help and participation in supporting this study.
432 This work was supported by the MRC funded G2P-UK National Virology Consortium; G2P-
433 UK; A National Virology Consortium to address phenotypic consequences of SARS-CoV-2
434 genomic variation (MR/W005611/1). JN, NT, DB, AE, BC and DB were also funded by The
435 Pirbright Institute’s BBSRC institute strategic programme grant (BBS/E/I/COV07001,
436 BBS/E/I/00007031, BBS/E/I/00007038, BBS/E/I/00007039 and BBS/E/I/00007034) with NT
437 receiving studentship support from BB/T008784/1. CB and DH were supported by funding
438 from the European Union’s Horizon 2020 Research and Innovation programme under grant
439 agreement No 773830: One Health European Joint Programme. We would also like to
440 acknowledge the National Institute for Communicable Diseases (NICD) and the KZN
441 Research Innovation and Sequencing Platform (KRISP), as part of the Network for Genomic
442 Surveillance in South Africa, for depositing the B.1.638 sequences, and the NICD, in particular
443 Daniel G. Amoako and Josie Everatt for providing feedback on the manuscript. The
444 Sequencing activities at the NICD were supported by: a conditional grant from the South
445 African National Department of Health as part of the emergency COVID-19 response; a
446 cooperative agreement between the National Institute for Communicable Diseases of the
447 National Health Laboratory Service and the UK Department of Health and Social Care,
448 managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project.

449 **Methods**

450 **Participants and Ethical Statement**

451 Healthy participants were recruited as part of the “COVID-19 vaccine responses after
452 extended immunisation schedules” (CONSENSUS) study [21]. Participants aged 70-90 years
453 in January 2021 were recruited through North London primary care networks. Sera samples
454 used in this study were taken at 3 and 20 weeks after 2 doses of Pfizer/BioNTech BNT162b2

455 (Mainz, Germany) COVID-19 vaccine given at a 3-week interval, as well as 4 weeks post 3rd
456 dose. The protocol was approved by Public Health England Research Ethics Governance
457 Group (reference NR0253; 18/01/21). All sera were heat inactivated at 56 degrees for 2 hours
458 prior to use.

459 **Cells**

460 Human embryonic kidney (HEK) 293T cells were used to generate lentiviral pseudoparticles
461 bearing the SARS-CoV-2 spike. HEK293T cells stably expressing human angiotensin
462 converting enzyme 2 (hACE2) under 1µg/mL puromycin (Gibco) selection were used for
463 neutralisation assays [56]. Cells were maintained in Dulbecco's Modified Eagle Medium
464 (Sigma-Aldrich) supplemented with 10% FBS (Life Science Production, UK), 1% 100 mM
465 sodium pyruvate (Sigma-Aldrich), 1% 200 mM L-glutamine (Sigma-Aldrich), and 1%
466 penicillin/streptomycin, 10,000 U/mL (Life Technologies) at 37°C in a humidified atmosphere
467 of 5% CO₂.

468 **Plasmids**

469 Mutant SARS-CoV-2 expression plasmids were generated by site-directed mutagenesis, by
470 using the QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent) or were
471 synthesised by Geneart (Thermo Fisher). All SARS-CoV-2 spike expression plasmids were
472 based on a codon optimised Wuhan-Hu-1 reference sequence (Genbank ID NC_045512.2)
473 [57], with the additional substitutions K1255*STOP (also referred to as Δ19 mutation or
474 cytoplasmic tail truncation). A list of the SARS-CoV-2 spike variants and their associated
475 mutations can be found in Supplemental Table 1. Some substitutions here differ from the
476 lineage defining sequence for the named variant (Pango); these were included as they were
477 substitutions that were highly sampled in submitted sequences and predicted to be a plausible
478 worst case antigenic escape for that lineage.

479 **Generating lentiviral based pseudotypes bearing the SARS-CoV-2 spike**

480 Lentiviral-based SARS-CoV-2 pseudotyped viruses were generated in HEK293T cells
481 incubated at 37°C, 5% CO₂ as previously described [58]. Briefly, cells were transfected with
482 900 ng of SARS-CoV-2 spike (see Supplemental Table 1), 600 ng p8.91 (encoding for HIV-1
483 gag-pol), 600 ng CSFLW (lentivirus backbone expressing a firefly luciferase reporter gene)
484 with PEI (1 µg/mL) transfection reagent. Supernatants containing pseudotyped SARS-CoV-2
485 were harvested and pooled at 48 and 72 hours post transfection, centrifuged at 1,300 x g for
486 10 minutes at 4 °C to remove cellular debris and stored at -80 °C. SARS-CoV-2
487 pseudoparticles were titrated on HEK293T cells stably expressing human ACE2 S-CoV-2 pps
488 and infectivity assessed by measuring luciferase luminescence after the addition of Bright-Glo
489 luciferase reagent (Promega) and read on a GloMax Multi+ Detection System (Promega).

490 **Micro neutralisation test (mVNT) using SARS-CoV-2 pseudoparticles**

491 Sera was diluted 1:5 in serum-free media in a 96-well plate in triplicate and titrated 3-fold. A
492 fixed titred volume of SARS-CoV-2 pseudoparticles was added at a dilution equivalent to 10⁵-
493 10⁶ signal luciferase units in 50 µL DMEM-10% and incubated with sera for 1 hour at 37 °C,
494 5% CO₂ (giving a final sera dilution of 1:10). Target cells expressing human ACE2 were then
495 added at a density of 2 x 10⁴ in 100 µL and incubated at 37 °C, 5% CO₂ for 48 hours. Firefly
496 luciferase activity was then measured after the addition of BrightGlo luciferase reagent on a
497 Glomax-Multi+ Detection System (Promega, Southampton, UK). Pseudotyped virus

498 neutralisation titres were calculating by interpolating the point at which there was 80%
499 reduction in reduction in luciferase activity, relative to untreated controls, neutralisation dose
500 80% (ND₈₀).

501 **ELISA RBD**

502 Antibody to the RBD of SARS-CoV-2 spike protein was measured using an in-house indirect
503 IgG RBD assay as described previously [59, 60]. Briefly, commercially synthesised
504 recombinant RBD subunit spike(Arg319-Phe541(V367F); SinoBiological Inc, Hong Kong,
505 PRC) with a C-terminal mouse Fc tag, was coated onto 96-well microtiter plates at 20 ng per
506 well at 4°C–8°C for a minimum of 16 hours. After washing and blocking, sera were analysed
507 at a dilution factor of 1 in 100 by serially diluting each serum sample starting at 1:100, (6-fold
508 with the highest dilution achieved 129600). The binding of IgG on the plate surface was
509 detected by using an anti-human IgG horseradish peroxidase antibody conjugate (Sigma-
510 Aldrich, Poole, UK) and 3,3',5,5'-Tetramethylbenzidine (Europa Bioproducts Ltd, Ely, UK). We
511 analysed samples in duplicate and evaluated optical density at 450 nm (OD₄₅₀) Samples were
512 analysed in the presence of known positive controls (collected from individuals with confirmed
513 SARS-CoV2 infection) and a calibrator sample ("negative" added to four wells; collected prior
514 to the pandemic). Titres are expressed as serum fold-dilution required to achieve a T/N (test
515 OD to negative OD) of 5 (T/N = 5 serves as cut-off for positive samples) by xy interpolation
516 from the RBD data series (dilution, x versus OD₄₅₀, y). Samples which were below the cut-
517 off in the initial dilution (ie negative), were expressed as <100.

518 **ELISA N and S Roche**

519 Sera samples were tested by commercial ELISA as previously described [21]. Nucleoprotein
520 (N) antibodies were measured as a marker of previous SARS-CoV-2 infection (Anti-SARS-
521 CoV-2 total antibody assay, Roche Diagnostics, Basel, Switzerland) and spike (S) protein
522 antibodies were measured as an indication of infection or vaccination (Elecsys Anti-SARS-
523 CoV-2 S total antibody assay, Roche Diagnostics: positive ≥ 0.8 arbitrary units (au)/mL to
524 assess vaccine response).

525 **Infectious SARS-CoV-2 VNT**

526 Sera were serially diluted 1:2 in media containing 1% foetal calf serum (FCS) and incubated
527 with 112.5 plaque forming units (PFU) of SARS CoV-2 (hCoV-19/England/02/2020,
528 EPI_ISL_407073, or Beta (B.1.351), kindly provided by Public Health England) for one hour
529 at 37 °C, 5% CO₂. 75 PFU of neutralisation mixture in a total of 200µl were then added to 96-
530 well plates containing a ~80-90% confluent monolayer of Vero-E6-TMPRSS2 (a gift from
531 Stuart Neil, KCL, London) cells were incubated for 6 days at 37 °C, 5% CO₂ in quadruplicate
532 per serum sample. Inoculum was then removed, and cells were fixed with formalin for 30
533 minutes before staining with 0.1% toluidine blue in PBS. ND₈₀ titres were calculated using a
534 Spearman and Karber formula. Thawed virus aliquots used for VNT were back-titrated 1:10
535 by TCID₅₀ on VERO-E6-TMPRSS2 cells to confirm the titre at time of use.

536 **Cartography**

537 Antigenic maps were made with antigenic cartography techniques described previously [50],
538 implemented in the R package *Racmacs* (version 1.1.12; <https://acorg.github.io/Racmacs/>). In
539 brief, titres were first converted into serum-antigen target distances, and sera and antigens
540 were then positioned on a map in a way that minimised the difference (residual sum of
541 squares) between target distances and corresponding map distances, using multidimensional
542 scaling. The target distance for each serum-antigen pair was calculated by subtracting the
543 logarithm (log₂) of the titre, from the highest log₂(titre) for the serum against any antigen; thus,


544 higher reciprocal titres resulted in shorter target distances. Multidimensional scaling was
545 carried out with 1000 random restart optimisations, to avoid local optima and increase the
546 likelihood of finding the best fit to the measured titres. The resulting maps were ordered
547 according to total error, and compared for self-consistency; the figures and descriptions in this
548 manuscript pertain to the maps with the lowest total error. Antigenic distances were measured
549 from the lowest error antigenic map.

550 The antigenic map of the ND80 titres was made based on titres from a subset of 14 sera: two
551 sera were removed before mapping, as their titres were consistently below or only marginally
552 above the detection limit, and they did therefore not contain valuable information for
553 cartography. ND80 titres from different experiments were merged without normalisation
554 procedures. For each serum, a single overall $\log_2(\text{titre})$ to D614G and B.1.617.2/Delta was
555 calculated by taking the mean of the $\log_2(\text{titre})$ values for these antigens across experiments.
556 Such average $\log_2(\text{titre})$ values were excluded (replaced with NA/‘missing value’) in case the
557 standard deviation of $\log_2(\text{titre})$ values for the antigen was equal to or exceeded 1.

558 To determine the optimal number of dimensions for representing the data, prediction
559 experiments were performed: antigenic maps were made while omitting a random 10% of
560 titres; the excluded titres were predicted according to their relative positions in the map; and
561 the predicted titres were then compared to the actual titres (on a log scale). Antigenic maps
562 were made in two, three, four and five dimensions, using 1000 optimizations; for each
563 dimension, 100 prediction tests were performed. The mean root mean square error (RMSE)
564 associated with the prediction of ND80 titres was 0.94 (SD: 0.15) for detectable titres and 1.32
565 (SD: 0.68) for non-detectable titres (i.e., below the limit of detection, <10), for two dimensions;
566 0.97 (SD: 0.14) and 1.37 (SD: 0.61) for three dimensions; 0.96 (SD: 0.14) and 1.34 (SD: 0.60)
567 for four dimensions; and 0.95 (SD: 0.14) and 1.35 (SD: 0.58) for five dimensions. The mean
568 RMSE associated with the prediction of RBD-ELISA titres was 0.55 (SD: 0.16) for detectable
569 titres and 1.27 (SD: 0.13) for non-detectable titres (i.e., below the limit of detection, <100), for
570 two dimensions; 0.56 (SD: 0.15) and 1.26 (SD: 0.10) for three dimensions; 0.56 (SD: 0.14)
571 and 1.25 (SD: 0.10) for four dimensions; and 0.56 (SD: 0.15) and 1.25 (SD: 0.11) for five
572 dimensions. Overall, for each dataset, the mean RMSE was similar across dimensions, and
573 in each case the mean RMSE for prediction of detectable titres corresponded to less than a
574 twofold dilution (one antigenic unit). Therefore, we considered two-dimensional maps
575 sufficient for representing the SARS-CoV-2 antigenic data.


576

577 **Figures and Figure Legends**




578 **Figure 1: Neutralising antibody responses generated following BNT162b2 vaccination.**

579 Neutralisation titres calculated using pseudotypes bearing the SARS-CoV-2 D614 (Wuhan)
580 spike and sera from a cohort of BNT162b2 vaccinated individuals (n=37), recruited as part of
581 the UK CONSENSUS trial, aged 70-79 (n=24, solid circle symbols) (A) or 80-89 (n=13, open
582 circle symbols) (B). Symbols in red represents samples taken from individuals who tested
583 positive for SARS-CoV-2 Nucleoprotein by ELISA, indicative of previous infection. Sera was
584 collected from the same individuals at 3- (n=37 total) and 20-weeks (n=35 total) post 2nd dose,
585 with a vaccination interval of 3 weeks between 1st and 2nd doses. Titres are expressed as
586 serum fold-dilution required to achieve 80% virus neutralisation, with the titre (ND80)
587 calculated by xy interpolation from the mVNT data series (dilution, x versus luciferase activity,
588 RLU, y). Statistical comparison of ND80 titres at 3 and 20 weeks was performed using a
589 Wilcoxon matched-pairs signed rank test (*, <0.05; ***, <0.001). Fold changes in median ND80
590 between 3 and 20 weeks are indicated. The detection limit of the assay is indicated with a
591 dotted line. The correlation between ND80 and S ELISA (Roche S) titres recorded from each
592 volunteer, was examined at 3 (n=37) (C) and 20 (n=35) (D) weeks post 2nd dose, with statistical
593 analysis of the matrix performed using a nonparametric Spearman correlation (r).




594
 595 **Figure 2: Neutralisation of SARS-CoV-2 variants of concern (VOC) by sera collected**
 596 **from BNT162b2 vaccinated individuals 3 weeks post 2nd dose.** (A) Schematics illustrating
 597 the spike mutation profiles of B.1, B.1.1.7 (Alpha), B.1.617.2 (Delta) and B.1.351 (Beta).
 598 Neutralisation of pseudotypes bearing the SARS-CoV-2 WT D614, D614G (B.1), Alpha, Delta
 599 or Beta spike were compared in the two age-stratified cohorts, 70-79 (n=24, solid circles) (B)
 600 and 80-89 (n=13, open circles) (C). Symbols in red represents samples taken from individuals
 601 who tested positive for SARS-CoV-2 Nucleoprotein by ELISA, indicative of previous infection.
 602 Titres are expressed as serum fold-dilution required to achieve 80% virus neutralisation,
 603 with the titre (ND80) calculated by xy interpolation from the mVNT data series (dilution, x versus
 604 luciferase activity, RLU, y). Statistical comparison of ND80 titres against the D614G reference
 605 was performed using a Wilcoxon matched-pairs signed rank test (**, <0.001; ****, <0.0001).
 606 Fold changes in median ND80, compared to D614G are indicated. The detection limit of the
 607 assay is indicated with a dotted line. The correlation between ND80 and S ELISA (Roche S)
 608 titres recorded for each volunteer (n=37), was then examined (D) for each VOC, with statistical
 609 analysis of the matrix performed using a nonparametric Spearman correlation (r). The same
 610 sera [70-79; n=24, solid circles (E) and 80-89; n=13, open circles (F)] was analysed with an
 611 RBD-based ELISA, using RBDs representing WT (NB; as indicated in (A) amino acid 614 is
 612 outside the RBD), Alpha, Beta and Delta spikes. Titres are expressed as serum fold-dilution
 613 required to achieve a T/N (test OD to negative OD) of 5 (T/N = 5 serves as cut-off for positive
 614 samples) by xy interpolation from the RBD data series (dilution, x versus OD450, y). Statistical
 615 comparison of RBD-ELISA titres was performed using a nonparametric Friedman test with
 616 Dunn's multiple comparisons of column means (**, <0.005; ****, <0.0001). Fold changes in
 617 median titre, compared to WT are indicated. The detection limit of the assay is indicated
 618 with a dotted line. The correlation between RBD-ELISA and S ELISA titres (Roche S) (G) or ND80

619 titres for each VOC (**H**) recorded from each volunteer (n=37) was then examined, with
 620 statistical analysis of the matrix performed using a nonparametric Spearman correlation (r).



621
 622 **Figure 3: Neutralisation of a broad library of SARS-CoV-2 variants by sera collected**
 623 **from BNT162b2 vaccinated individuals. (A)** Schematics illustrating the spike mutation
 624 profiles of thirteen SARS-CoV-2 variants, variants under investigation (VUIs) or VOCs
 625 including B.1, C.37 (Lambda) and B.1.621 (Mu). **(B)** Neutralisation of pseudotypes bearing
 626 these spike proteins were compared using a sub-section (n=16) of sera from the BNT162b2-
 627 vaccinated (3-week dosing interval, 3-weeks post 2nd dose) age-stratified cohorts (70-79,
 628 n=11, solid circles; 80-89 n=5, open circles). The single symbol in red represents a sample
 629 taken from an individual who tested positive for SARS-CoV-2 Nucleoprotein by ELISA,
 630 indicative of previous infection. Titres are expressed as serum fold-dilution required to
 631 achieve 80% virus neutralisation, with the titre (ND80) calculated by xy interpolation from the
 632 mVNT data series (dilution, x versus luciferase activity, RLU, y). Statistical comparison of ND80 titres

633 against the D614G reference was performed using a Wilcoxon matched-pairs signed rank test
 634 (*, <0.05; **, <0.005, ***, <0.001; ****, <0.0001). The separate graphs represent experiments
 635 performed on different days, with each assay including the D614G pseudotype as a reference.
 636 Fold changes in median ND80, compared to D614G are indicated. The detection limit of the
 637 assay is indicated with a dotted line. **(C)** Two-dimensional antigenic map of variants, based
 638 on the ND80 titres in (B). Multidimensional scaling was used to position the sera and variants
 639 to best fit target distances derived from the titres. The map is the lowest error solution of 1000
 640 optimisations. Variants are represented by solid circles, sera by open squares (with the
 641 Nucleoprotein-ELISA-positive serum in red). Two sera were not used in mapping because of
 642 titres consistently below the detection limit. The spacing between grid lines represents one
 643 antigenic unit, equivalent to a two-fold dilution in ND80 titres. **(D)** The same sera (70-79, n=11,
 644 solid circles; 80-89, n=5, open circles) were analysed with an RBD-based ELISA, using RBDs
 645 representing WT, Alpha, Beta and Delta spike (data replotted from Fig.2E/F for comparison)
 646 as well as spikes containing the individual mutations K417N, L452R, T478K, E484Q, E484K
 647 and E484D (relative to WT). Titres are expressed as serum fold-dilution required to achieve a
 648 T/N (test OD to negative OD) of 5 (T/N = 5 serves as cut-off for positive samples) by xy
 649 interpolation from the RBD data series (dilution, x versus OD450, y). Statistical comparison of
 650 RBD-ELISA titres was performed using a nonparametric Friedman test with Dunn's multiple
 651 comparisons of column means (*, <0.05; ***, <0.001; ****, <0.0001). Fold changes in median
 652 titre, compared to WT are indicated. The detection limit of the assay is indicated with a dotted
 653 line.



654
 655 **Figure 4: Neutralising antibody responses to Omicron after a 3rd booster dose of**
 656 **BNT162b2. (A)** Schematic illustrating the spike mutation profiles of BA.1 (Omicron).
 657 Neutralisation titres calculated using pseudotypes bearing the SARS-CoV-2 D614G or
 658 Omicron spike and sera from a cohort of BNT162b2 vaccinated individuals (n=19), recruited
 659 as part of the UK CONSENSUS trial, aged 70-79 (n=12, solid circle symbols) **(B)** or 80-89
 660 (n=7, open circle symbols) **(C)**. Sera samples were taken from the same volunteers at the
 661 indicated times post 2nd or 3rd doses of vaccination. Symbols in red represent samples taken
 662 from individuals who tested positive for SARS-CoV-2 Nucleoprotein by ELISA, indicative of

663 previous infection. Titres are expressed as serum fold-dilution required to achieve 80% virus
664 neutralisation, with the titre (ND80) calculated by xy interpolation from the mVNT data series
665 (dilution, x versus luciferase activity, RLU, y). Fold changes in median ND80 between D614G
666 and Omicron are indicated. The detection limit of the assay is indicated with a dotted line. The
667 correlation between Omicron ND80 and S ELISA (Roche S) titres recorded from each
668 volunteer, was examined at 20 weeks post 2nd dose (**D**) and 4 weeks post 3rd dose (both
669 n=19) (**E**), with statistical analysis of the matrix performed using a nonparametric Spearman
670 correlation (r).





671








672 References





- 673 1. Polack, F.P., et al., *Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine*. N
674 Engl J Med, 2020. **383**(27): p. 2603-2615.
- 675 2. Folegatti, P.M., et al., *Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine
676 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised
677 controlled trial*. Lancet, 2020. **396**(10249): p. 467-478.
- 678 3. Agency, U.H.S., *COVID-19: the green book, chapter 14a. Coronavirus (COVID-19)
679 vaccination information for public health professionals.*, U.H.S. Agency, Editor. 2021,
680 UK Government.
- 681 4. Collier, D.A., et al., *Age-related immune response heterogeneity to SARS-CoV-2
682 vaccine BNT162b2*. Nature, 2021. **596**(7872): p. 417-422.
- 683 5. Kawasuji, H., et al., *Age-Dependent Reduction in Neutralization against Alpha and
684 Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity*. Microbiol
685 Spectr, 2021. **9**(3): p. e0056121.
- 686 6. Peacock, T.P., et al., *SARS-CoV-2 one year on: evidence for ongoing viral adaptation*.
687 Journal of General Virology, 2021. **102**(4).
- 688 7. Konings, F., et al., *SARS-CoV-2 Variants of Interest and Concern naming scheme
689 conducive for global discourse*. Nat Microbiol, 2021. **6**(7): p. 821-823.
- 690 8. Davies, N.G., et al., *Estimated transmissibility and impact of SARS-CoV-2 lineage
691 B.1.1.7 in England*. Science, 2021. **372**(6538).
- 692 9. Rambaut, A., et al., *Preliminary genomic characterisation of an emergent SARS-CoV-
693 2 lineage in the UK defined by a novel set of spike mutations*. 2020: virological.org.
- 694 10. Tegally, H., et al., *Detection of a SARS-CoV-2 variant of concern in South Africa*.
695 Nature, 2021. **592**(7854): p. 438-443.
- 696 11. Faria, N.R., et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in
697 Manaus, Brazil*. Science (New York, N.Y.), 2021. **372**(6544): p. 815-821.
- 698 12. Scheepers, C., et al., *Emergence and phenotypic characterization of C.1.2, a globally
699 detected lineage that rapidly accumulated mutations of concern*. medRxiv, 2021: p.
700 2021.08.20.21262342.
- 701 13. UK Health Security Agency, *Technical briefing 31, in SARS-CoV-2 variants of concern
702 and variants under investigation in England*. 2021, UK HSA.
- 703 14. European Centre for Disease Prevention and Control, *SARS-CoV-2 variants of
704 concern as of 13 December 2021*. 2021, ECDC.
- 705 15. Mlcochova, P., et al., *SARS-CoV-2 B.1.617.2 Delta variant replication and immune
706 evasion*. Nature, 2021. **599**(7883): p. 114-119.
- 707 16. Cherian, S., et al., *SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R,
708 in the Second Wave of COVID-19 in Maharashtra, India*. Microorganisms, 2021. **9**(7):
709 p. 1542.
- 710 17. Cele, S., et al., *SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer
711 BNT162b2 elicited neutralization and requires ACE2 for infection*. medRxiv, 2021: p.
712 2021.12.08.21267417.

- 713 18. Dejnirattisai, W., et al., *Reduced neutralisation of SARS-CoV-2 Omicron-B.1.1.529*
714 *variant by post-immunisation serum.* medRxiv, 2021: p. 2021.12.10.21267534.
- 715 19. Cameroni, E., et al., *Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron*
716 *antigenic shift.* bioRxiv, 2021: p. 2021.12.12.472269.
- 717 20. Garcia-Beltran, W.F., et al., *mRNA-based COVID-19 vaccine boosters induce*
718 *neutralizing immunity against SARS-CoV-2 Omicron variant.* medRxiv, 2021: p.
719 2021.12.14.21267755.
- 720 21. Subbarao, S., et al., *Robust antibody responses in 70-80-year-olds 3 weeks after the*
721 *first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January*
722 *to February 2021.* Euro Surveill, 2021. **26**(12).
- 723 22. Noori, M., et al., *Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing*
724 *antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A*
725 *systematic review of in vitro studies.* Reviews in Medical Virology. **n/a**(n/a): p. e2277.
- 726 23. Bian, L., et al., *Impact of the Delta variant on vaccine efficacy and response strategies.*
727 *Expert Review of Vaccines*, 2021. **20**(10): p. 1201-1209.
- 728 24. Vacharathit, V., et al., *CoronaVac induces lower neutralising activity against variants*
729 *of concern than natural infection.* The Lancet Infectious Diseases, 2021. **21**(10): p.
730 1352-1354.
- 731 25. Hoffmann, M., et al., *SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and*
732 *evades antibodies induced by infection and vaccination.* Cell reports, 2021. **36**(3): p.
733 109415-109415.
- 734 26. Liu, C., et al., *Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and*
735 *convalescent serum.* Cell, 2021. **184**(16): p. 4220-4236.e13.
- 736 27. Collier, D.A., et al., *Age-related immune response heterogeneity to SARS-CoV-2*
737 *vaccine BNT162b2.* Nature, 2021. **596**(7872): p. 417-422.
- 738 28. Parry, H., et al., *mRNA vaccination in people over 80 years of age induces strong*
739 *humoral immune responses against SARS-CoV-2 with cross neutralization of P.1*
740 *Brazilian variant.* eLife, 2021. **10**: p. e69375.
- 741 29. Greaney, A.J., et al., *Mapping mutations to the SARS-CoV-2 RBD that escape binding*
742 *by different classes of antibodies.* Nat Commun, 2021. **12**(1): p. 4196.
- 743 30. Cele, S., et al., *SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer*
744 *BNT162b2 elicited neutralization and requires ACE2 for infection.* medRxiv, 2021.
- 745 31. Scheepers, C., et al., *The continuous evolution of SARS-CoV-2 in South Africa: a new*
746 *lineage with rapid accumulation of mutations of concern and global detection.*
747 medRxiv, 2021: p. 2021.08.20.21262342.
- 748 32. Laiton-Donato, K., et al., *Characterization of the emerging B.1.621 variant of interest*
749 *of SARS-CoV-2.* Infect Genet Evol, 2021. **95**: p. 105038.
- 750 33. Tablizo, F.A., et al., *Genome sequencing and analysis of an emergent SARS-CoV-2*
751 *variant characterized by multiple spike protein mutations detected from the Central*
752 *Visayas Region of the Philippines.* medRxiv, 2021: p. 2021.03.03.21252812.
- 753 34. Tada, T., et al., *Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-*
754 *elicited Antibodies in Individuals With and Without Previous History of Infection.*
755 bioRxiv, 2021: p. 2021.10.19.463727.
- 756 35. Uriu, K., et al., *Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and*
757 *Vaccine Serum.* N Engl J Med, 2021.
- 758 36. Arora, P., et al., *The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and*
759 *evades vaccine-induced antibodies with high efficiency.* Cell Mol Immunol, 2021.
760 **18**(12): p. 2673-2675.
- 761 37. Harvey, W.T., et al., *SARS-CoV-2 variants, spike mutations and immune escape.*
762 *Nature Reviews Microbiology*, 2021. **19**(7): p. 409-424.
- 763 38. Collier, D.A., et al., *Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited*
764 *antibodies.* Nature, 2021. **593**(7857): p. 136-141.
- 765 39. Graham, M.S., et al., *Changes in symptomatology, reinfection, and transmissibility*
766 *associated with the SARS-CoV-2 variant B.1.1.7: an ecological study.* Lancet Public
767 Health, 2021. **6**(5): p. e335-e345.

- 768 40. Liu, Y., et al., *The N501Y spike substitution enhances SARS-CoV-2 infection and*
769 *transmission*. Nature, 2021.
- 770 41. Cantoni, D., et al., *Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by*
771 *convalescent sera from SARS-CoV-2 infected Patients*. bioRxiv, 2021: p.
772 2021.08.17.456606.
- 773 42. Liu, K., et al., *Binding and molecular basis of the bat coronavirus RaTG13 virus to*
774 *ACE2 in humans and other species*. Cell, 2021. **184**(13): p. 3438-3451.e10.
- 775 43. McCarthy, K.R., et al., *Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive*
776 *antibody escape*. Science, 2021. **371**(6534): p. 1139-1142.
- 777 44. Peacock, T.P., et al., *The furin cleavage site in the SARS-CoV-2 spike protein is*
778 *required for transmission in ferrets*. Nature Microbiology, 2021. **6**(7): p. 899-909.
- 779 45. Thorne, L.G., et al., *SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection*
780 *to macrophage inflammation*. The EMBO journal, 2021. **40**(15): p. e107826-e107826.
- 781 46. UK Health Security Agency, *Risk assessment for SARS-CoV-2 variant: VUI-21OCT-*
782 *01 AY.4.2*. 2021, UK HSA.
- 783 47. Lassaunière, R., et al., *Neutralisation of SARS-CoV-2 Delta sub-lineage AY.4.2 and*
784 *B.1.617.2+E484K by BNT162b2 mRNA vaccine-elicited sera*. medRxiv, 2021: p.
785 2021.11.08.21266075.
- 786 48. Payne, R.P., et al., *Immunogenicity of standard and extended dosing intervals of*
787 *BNT162b2 mRNA vaccine*. Cell, 2021. **184**(23): p. 5699-5714.e11.
- 788 49. Koel, B.F., et al., *Substitutions near the receptor binding site determine major antigenic*
789 *change during influenza virus evolution*. Science, 2013. **342**(6161): p. 976-9.
- 790 50. Smith, D.J., et al., *Mapping the antigenic and genetic evolution of influenza virus*.
791 Science, 2004. **305**(5682): p. 371-6.
- 792 51. Mansfield, K.L., et al., *Flavivirus-induced antibody cross-reactivity*. J Gen Virol, 2011.
793 **92**(Pt 12): p. 2821-2829.
- 794 52. Horton, D.L., et al., *Quantifying antigenic relationships among the lyssaviruses*. J Virol,
795 2010. **84**(22): p. 11841-8.
- 796 53. Stamatatos, L., et al., *mRNA vaccination boosts cross-variant neutralizing antibodies*
797 *elicited by SARS-CoV-2 infection*. Science, 2021.
- 798 54. Spencer, A.J., et al., *The ChAdOx1 vectored vaccine, AZD2816, induces strong*
799 *immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in*
800 *preclinical studies*. bioRxiv, 2021: p. 2021.06.08.447308.
- 801 55. Dupont, L., et al., *Neutralizing antibody activity in convalescent sera from infection in*
802 *humans with SARS-CoV-2 and variants of concern*. Nat Microbiol, 2021. **6**(11): p.
803 1433-1442.
- 804 56. Peacock, T.P., et al., *The furin cleavage site in the SARS-CoV-2 spike protein is*
805 *required for transmission in ferrets*. Nat Microbiol, 2021. **6**(7): p. 899-909.
- 806 57. McKay, P.F., et al., *Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine*
807 *candidate induces high neutralizing antibody titers in mice*. Nature communications,
808 2020. **11**(1): p. 3523-3523.
- 809 58. Thakur, N., et al., *Production of Recombinant Replication-defective Lentiviruses*
810 *Bearing the SARS-CoV or SARS-CoV-2 Attachment Spike Glycoprotein and Their*
811 *Application in Receptor Tropism and Neutralisation Assays*. Bio-protocol, 2021.
812 **11**(21): p. e4249.
- 813 59. Amirthalingam, G., et al., *Seroprevalence of SARS-CoV-2 among Blood Donors and*
814 *Changes after Introduction of Public Health and Social Measures, London, UK*. Emerg
815 Infect Dis, 2021. **27**(7): p. 1795-1801.
- 816 60. Jeffery-Smith, A., et al., *Antibodies to SARS-CoV-2 protect against re-infection during*
817 *outbreaks in care homes, September and October 2020*. Euro Surveill, 2021. **26**(5).









A.**B.****C.****D.**

A.

B.1.1.529/Omicron

**B.****C.****D.****E.**